

**EVALUATION FORM**  
*Grand Rounds in Oncology:*  
*How the Experts Treat Cancer Module 1 (Myeloma)*  
**Release Date: July 31, 2010**

---

The City of Hope respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. *You must complete this evaluation form and the posttest to receive a CME credit certificate.*

**Please answer the following questions by circling the appropriate rating:**

5 = Outstanding      4 = Good      3 = Satisfactory      2 = Fair      1 = Poor

**Extent to Which Program Activities Met the Identified Objectives**

*Upon successful completion of this educational activity, participants should be better able to:*

- Apply clinical advancements in the treatment of patients with newly diagnosed, relapsed, and refractory multiple myeloma 5 4 3 2 1
- Compare and contrast traditional systemic and new targeted therapies for treating patients with multiple myeloma 5 4 3 2 1
- Interpret current clinical trials designed to improve treatment and patient outcomes 5 4 3 2 1

**Overall Effectiveness of the Activity**

- Was timely and will influence how I practice 5 4 3 2 1
- Will assist me in improving patient care 5 4 3 2 1
- Fulfilled my educational needs 5 4 3 2 1
- Avoided commercial bias or influence 5 4 3 2 1

**Impact of the Activity**

*The information presented:*

(check all that apply)

- |  |  |
|--|--|
| <input type="checkbox"/> Reinforced my current practice/treatment habits   | <input type="checkbox"/> Will improve my practice/patient outcomes |
| <input type="checkbox"/> Provided new ideas or information I expect to use | <input type="checkbox"/> Enhanced my current knowledge base        |

Will the information presented cause you to make any changes in your practice?

- Yes       No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

---

---

How committed are you to making these changes?

(Very committed)      5      4      3      2      1      (Not at all committed)

**Future Activities**

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes       No

**EVALUATION FORM**

*Grand Rounds in Oncology: How the Experts Treat Cancer Module 1 (Myeloma)*

Please list any other topics that would be of interest to you for future educational activities:

---

---

**Follow-up**

As part of our ongoing continuous quality improvement effort, we conduct post-activity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I would be interested in participating in a follow-up survey
- No, I'm not interested in participating in a follow-up survey

Additional comments about this activity:

---

---

**Request for Credit**

If you wish to receive acknowledgement of participation for this activity, please complete the posttest by selecting the best answer to each question. Complete this evaluation verification of participation and submit by email to [CME@coh.org](mailto:CME@coh.org) by clicking on the link below the posttest; or mail to City of Hope Office of Continuing Medical Education, 1500 East Duarte Road, Duarte, CA 91010; or fax to 626-301-8939.

Name \_\_\_\_\_ Degree \_\_\_\_\_

Organization \_\_\_\_\_ Specialty \_\_\_\_\_

Address \_\_\_\_\_

City, State, Zip \_\_\_\_\_

Telephone \_\_\_\_\_ Fax \_\_\_\_\_ E-Mail \_\_\_\_\_

I certify my actual time spent to complete this educational activity to be:

- I participated in the activity *Improving Outcomes in Multiple Myeloma* and claim 1.0 credits.

Signature \_\_\_\_\_ Date \_\_\_\_\_

**Post-test Answer Form**

1	2	3	4

## CME POSTTEST

### *Grand Rounds in Oncology: How the Experts Treat Cancer Module 1 (Myeloma)*

---

1. High-risk cytogenetics include all of the following **EXCEPT**:
  - A. del17
  - B. t4, 14
  - C. hyperdiploidy
  
2. In the ECOG E4A03 trial of lenalidomide plus high dose decadron versus lenalidomide plus low dose decadron, which of the following is true?
  - A. The ORR (overall response rate) was the same for the high dose and low dose decadron arm.
  - B. The overall survival was the same for the high dose and low dose arms.
  - C. The incidence of thromboembolic events was the same for both arms.
  
3. EBMT response criteria for complete remission includes all of the following **EXCEPT**:
  - A. <5% marrow plasmacytosis
  - B. Normal free light ratio
  - C. Negative immunofixation
  
4. Which of the following is true about carfilzomib (PX171-004)?
  - A. It is a proteasome inhibitor
  - B. The incidence of neuropathy is greater than with bortezomib
  - C. The ORR in bortezomib-treated patients is 46%